Market Closed -
Nasdaq
04:00:00 2024-05-09 pm EDT
5-day change
1st Jan Change
968
USD
+1.28%
+3.24%
+10.21%
Sales 2024 *
13.85B
Sales 2025 *
14.95B
Capitalization
105B
Net income 2024 *
4.06B
Net income 2025 *
4.47B
EV / Sales 2024 *
6.95
x
Net cash position
2024
*
9.06B
Net cash position
2025
*
14.79B
EV / Sales 2025 *
6.06
x P/E ratio 2024 *
27.1
x
P/E ratio 2025 *
24.5
x
Employees
13,677
Yield 2024 *
-
Yield 2025 *
-
Free-Float
78.34%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
5 minutes 15 minutes 30 minutes 1 hour 1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
Regeneron Pharmaceuticals, Inc. Announces Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness Within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks
May. 08
CI
UBS Raises Regeneron Pharmaceuticals Price Target to $1,124 From $1,099, Maintains Buy Rating
May. 07
MT
Deutsche Bank Adjusts Price Target on Regeneron Pharmaceuticals to $870 From $880, Hold Rating Kept
May. 03
MT
Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $1,180 From $1,126
May. 03
MT
Morgan Stanley Raises Price Target on Regeneron Pharmaceuticals to $1,183 From $1,177
May. 02
MT
Piper Sandler Adjusts Regeneron Pharmaceuticals' Price Target to $1,000.25 From $1,016
May. 02
MT
RBC Cuts Price Target on Regeneron Pharmaceuticals to $1,185 From $1,189
May. 02
MT
Global markets live: Etsy, Qualcomm, Carvana, Rio Tinto, Apple...
May. 02
Sector Update: Health Care Stocks Mixed Premarket Thursday
May. 02
MT
Transcript : Regeneron Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 02, 2024
May. 02
Regeneron: Adjusted EPS down 4% in Q1
May. 02
CF
Fed, Earnings Outlooks Lift Wall Street Pre-Bell; Asia Mixed, Europe Off
May. 02
MT
Tranche Update on Regeneron Pharmaceuticals, Inc.'s Equity Buyback Plan announced on February 3, 2023.
May. 02
CI
Regeneron Pharmaceuticals 1Q Revenue Declines Amid Lower EYLEA Sales
May. 02
DJ
Regeneron Pharmaceuticals' Q1 Non-GAAP Net Income, Revenue Decline
May. 02
MT
More news
UBS Raises Regeneron Pharmaceuticals Price Target to $1,124 From $1,099, Maintains Buy Rating
May. 07
MT
Deutsche Bank Adjusts Price Target on Regeneron Pharmaceuticals to $870 From $880, Hold Rating Kept
May. 03
MT
Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $1,180 From $1,126
May. 03
MT
Morgan Stanley Raises Price Target on Regeneron Pharmaceuticals to $1,183 From $1,177
May. 02
MT
Piper Sandler Adjusts Regeneron Pharmaceuticals' Price Target to $1,000.25 From $1,016
May. 02
MT
More recommendations
Regeneron : BPA ajusté en repli de 4% au 1er trimestre
May. 02
Borsa di Italia: qualcuno ci capisce qualcosa?
May. 02
Quelqu'un y comprend quelque chose ?
May. 02
IN DIRETTA DAI MERCATI: Amplifon, Aena, Generali, Nexi, Stellantis, Terna, Zignago Vetro, Novo Nordisk, Pandora, ING, eBay...
May. 02
En Direct des Marchés : Teleperformance, Worldline, Neoen, Imerys, Novo Nordisk, DoorDash, Shell...
May. 02
More news 1 day +1.28%
1 week +3.24%
Current month +8.68%
1 month +2.55%
3 months +1.53%
6 months +20.96%
Current year +10.21%
More quotes
Managers
Title Age Since
Founder
64
88-01-07
Chief Executive Officer
71
88-01-07
Director of Finance/CFO
54
02-12-31
Members of the board
Title Age Since
Director/Board Member
71
10-11-11
Chief Executive Officer
71
88-01-07
Director/Board Member
82
91-05-31
More insiders
Date
Price
Change
Volume
24-05-08
955.8
-1.46%
424,925
24-05-07
970
+1.18%
362,320
24-05-06
958.6
+0.17%
352,000
24-05-03
957
+2.07%
547,373
24-05-02
937.6
+3.78%
1,066,980
Delayed Quote
Nasdaq, May 09, 2024 at 04:00 pm EDT
More quotes
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows:
- revenues from product sales (56.6%);
- revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%);
- other (3%): primarily revenues from sales of technology licenses and subcontracted research services.
At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
More about the company
Last Close Price
955.8
USD
Average target price
1,034
USD
Spread / Average Target
+8.24%
Consensus
1st Jan change
Capi.
+10.21% 105B +2.97% 108B +1.57% 23.46B -12.77% 21.72B -7.05% 18.64B -37.64% 17.45B -6.50% 17.19B +6.00% 13.99B +37.20% 12.53B +330.95% 8.81B
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1